国际眼科杂志2018，Vol.18Issue(5)：922-925,4.DOI:10.3980/j.issn.1672-5123.2018.5.39
康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿
Intravitreal injection of Conbercept for macular edema due to branch retinal vein occlusion
摘要
Abstract
AIM:To compare the efficacy of one initial intravitreal Conbercept injection(IVR) followed by pro re nata(PRN) dosing with that of three initial monthly IVR followed by PRN dosing in patients with macular edema (ME) after branch retinal vein occlusion (BRVO). METHODS: The clinical data of 35 cases were retrospectively analyzed; 20 received one initial IVR injection (1+PRN group) and 15 cases received 3-monthly IVRs (3+PRN). Both groups were followed monthly for 12mo. The best-corrected visual acuity (BCVA) and the macular central retinal thickness (CMT) on optical coherence tomography were evaluated before and after treatment, and the BCVA results were converted to the LogMAR visual acuity. RESULTS: The mean LogMAR BCVA and CMT, respectively,improved from 0.58士0.21 to 0.34士0.18 and from 561士65μ m to 252士69μ m in the"1+PRN冶 group (P<0 05) and from 0.64士0.21 to 0.29士0.13 and from 585士87μ m to 242士56μ m in the"3+PRN冶 group (P>0.05). During the study period, the mean total number of injections was significantly smaller in the"1+PRN冶 group than in the"3+PRN冶 group (2. 3士1. 2 and 4. 1士1. 1, respectively,P<0.05). No serious complications related to the IVB injections developed in either group. CONCLUSION: The two methods are both safe and effective for the treatment of BRVO combined with ME.关键词
视网膜分支静脉阻塞/康柏西普/治疗方案Key words
branch retinal vein occlusion/Conbercept/therapeutic regimen引用本文复制引用
蔡骐,周跃,黄黎黎,黄晓波,朱妍,宋愈..康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿[J].国际眼科杂志,2018,18(5):922-925,4.基金项目
南通市科技项目(No.MS22015085)Nantong Science and Technology Project(No.MS22015085) （No.MS22015085）
